- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03914131
Clinical Trial Scheme of Xinnaoning Capsule
To Evaluate the Efficacy and Safety of Xinnaoning Capsule in Treating Chronic Stable Angina Pectoris (Qi Stagnation and Blood Stasis Syndrome) : a Randomized, Double-blind, Parallel Controlled, Multi-center Clinical Study
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Fengqin Xu, Doctor
- Phone Number: 010-62835113 010-62835113
- Email: 18800021979@163.com
Study Contact Backup
- Name: Chunsheng Qiao
- Phone Number: 010-58462584 010-58462584
- Email: qiaocs@drugevaluation.cn
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100091
- Recruiting
- Xiyuan Hospital, Chinese Academy of Traditional Chinese Medicine
-
Contact:
- Fengqin xu, Doctor
- Phone Number: 010-62835113
- Email: 18800021979@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Refer to the Guidelines for Diagnosis and Treatment of Chronic Stable Angina issued by the Chinese Medical Association in 2007, 2012ACP/ACCF/AHA/AATS/PCNA/STS (Guidelines for Diagnosis and Management of Stable Ischemic Heart Disease: American Heart Foundation/American Heart Association/American Medical Association/American Thoracic Surgery Association/American Association for Cardiovascular Preventive Nursing/American Association for Cardiovascular Angiography and Intervention/American Thoracic Association The Diagnosis of Stable Ischemic Heart Disease: Guidelines for Clinical Practice, Guidelines for the Management of Stable Coronary Artery Diseases in 2013 ESC, which can diagnose coronary heart disease in accordance with any of the following:
- Has a clear history of old myocardial infarction, or PCI history, or bypass history
- Coronary angiography (results indicate at least one coronary artery stenosis with stenosis (>50%) or coronary CTA suggests stenosis with stenosis (>50%)
- Those who met the diagnostic criteria of chronic stable angina pectoris: those who had a history of angina pectoris more than 1 month and had no significant changes in the degree, frequency, nature and inducing factors of angina pectoris
- The severity of angina pectoris of the Canadian Cardiovascular Society (CCS) was classified as Grade I to Grade III, and angina pectoris occurred more than twice a week
- The syndrome differentiation of TCM is Qi stagnation and blood stasis syndrome
- Age ranges from 30 to 79 years old
- Sign the informed consent
Exclusion Criteria:
- Severe cardiopulmonary insufficiency (grade III, IV, severe abnormal pulmonary function);
- Poor control of hypertension (systolic blood pressure (> 160 mmHg) or diastolic blood pressure (> 100 mmHg) after treatment;
- Complicated with liver and kidney function damage, ALT, AST (> 1.5 times of the upper limit of normal value), or Cr (> the upper limit of normal value), combined with hematopoietic system and other serious primary diseases;
- Acute myocardial infarction within 3 months after interventional therapy;
- Cardiac pacemaker;
- Pregnancy, lactation or pregnancy planners;
- Anaphylactic constitution or allergic to known ingredients of research drugs;
- Chest pain caused by other causes (moderate anemia, hyperthyroidism, etc.)
- Those who participated in other clinical drug trials within one month;
- According to the judgement of the researchers, it is not advisable to participate in clinical researchers.
- Other factors affecting ST-T changes in ECG, such as myocardial hypertrophy, left bundle branch block, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: study group
Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals. The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule 3 tablets per time, 3 times per day, orally, after meals. Dosage form:Capsule |
Xinnaoning Capsule used in study group(treatment period) is the true drug that the investigators are to evaluate.
Other Names:
Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
Other Names:
|
Placebo Comparator: control group
Introduction period: 2 weeks, time window (±2 days). Dosage regimen: Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals. The treatment period: 12 weeks, time window (±4 days). Dosage regimen:Take Xinnaoning Capsule Simulator 3 tablets per time, 3 times per day, orally, after meals. Dosage form:Capsule |
Xinnaoning Capsule Simulator used in control group and introduction period(both groups) is the placebo to reduce the risk of bias.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the changes of curative effect of angina pectoris symptoms
Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
The number of angina attacks, duration, degree of pain, and the dosage of nitroglycerin are used as indicators for scoring.
Score ranges 0-15, the higher the score, the more severe the angina.
|
Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Therapeutic effect of TCM syndromes
Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
The main symptoms of Qi stagnation and blood stasis syndrome are chest pain, chest tightness, secondary symptoms such as palpitation, shortness of breath, chest swelling, fatigue, dark lips, dizziness, veins at the base of tongue, irritability, etc.
The severity and presence of these symptoms are used as criteria for scoring.
Score ranges 0-28.The higher the score, the more serious it is.
|
Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
Grading changes of severity of angina pectoris
Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
Reference to Canadian Cardiovascular Society (CCS) Angina Severity Classification Standard。Ⅰ:General physical activity does not cause angina pectoris, such as walking and going upstairs, but tension, rapid or sustained exertion can cause the onset of angina pectoris.Ⅱ:Daily physical activity is slightly restricted.
Walking fast or upstairs, climbing high, walking after meals or upstairs, walking in cold or wind, and emotional excitement can cause angina or only occur within a few hours after waking up.
It is limited to walk more than 200 meters or climb stairs above one floor at normal speed.Ⅲ:Daily physical activity is obviously limited, and angina pectoris can occur when walking 100-200 m at normal speed or climbing a staircase.Ⅳ:Angina symptoms can occur when you are slightly active or at rest.
|
Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
Changes in the number of angina attacks per week
Time Frame: through study completion, an average of 14 weeks
|
Frequency of angina pectoris episodes per week
|
through study completion, an average of 14 weeks
|
Nitroglycerin dosage
Time Frame: through study completion, an average of 14 weeks
|
basic treatment
|
through study completion, an average of 14 weeks
|
Seattle Angina Questionnaire,SAQ
Time Frame: Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
The Seattle Angina Questionnaire (SAQ) measured a total of L9 problems,including physical activity limitation, stable state of angina, frequency of angina attack, satisfaction with treatment, and knowledge of disease.
A kind of Assessment of Seattle Scale: The Seattle Angina Scale was divided into 5 items and 19 items: Physical Activity Restriction (PL, Question 1), Angina Stable State (AS, Question 2), Angina Attack (AF, Question 3-4), Treatment Satisfaction (TS, Question 5-8), Disease Cognition (DS, Question 9-11), 19 items of 5 items and the total score of SAQ.
The formula is transformed into standard integral, standard integral = (actual score - the lowest score in this respect) / (the highest score in this respect - the lowest score in this respect) * 100, the higher the score, the better the quality of life and the state of body function of patients.
|
Visit1:introduction period,-14±2days; Visit2:treatment period,-4~0day; Visit3:treatment period,4weeks±4days; Visit4:treatment period,8weeks±4days; Visit5:treatment period, 12weeks±4days
|
Blood homocysteine
Time Frame: visti1:treatment period,-4~0day; Visit2:treatment period,12weeks±4days
|
The changes of blood HCY before and after treatment are compared between the two groups.
|
visti1:treatment period,-4~0day; Visit2:treatment period,12weeks±4days
|
Incidence of cardiovascular events
Time Frame: Visit1:treatment period,-4~0day; Visit2:treatment period,4weeks±4days; Visit3:treatment period,8weeks±4days; Visit4:treatment period, 12weeks±4days
|
Sudden cardiac death, acute myocardial infarction, heart failure, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, malignant arrhythmia, cardiogenic cerebrovascular accident, angina pectoris requiring hospitalization, etc.
|
Visit1:treatment period,-4~0day; Visit2:treatment period,4weeks±4days; Visit3:treatment period,8weeks±4days; Visit4:treatment period, 12weeks±4days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Fengqin Xu, Doctor, Xiyuan Hospital of China Academy of Chinese Medical Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Pain
- Neurologic Manifestations
- Disease
- Gastrointestinal Diseases
- Intestinal Diseases
- Malabsorption Syndromes
- Chest Pain
- Syndrome
- Angina Pectoris
- Angina, Stable
- Blind Loop Syndrome
Other Study ID Numbers
- DHZD-XNNJN-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Stable Angina Pectoris
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...UnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe First Affiliated Hospital of Zhejiang Chinese Medical UniversityUnknownChronic Stable Angina PectorisChina
-
Zhejiang Chinese Medical UniversityThe Third Affiliated hospital of Zhejiang Chinese Medical University; The First...Unknown
-
Fundação Educacional Serra dos ÓrgãosCompletedChronic Stable Angina PectorisBrazil
-
Neovasc Inc.Shockwave Medical, Inc.Active, not recruitingAngina Pectoris | Chronic Stable Angina | Angina Pectoris, StableNetherlands, Spain, United Kingdom, Germany, Italy, Switzerland, Belgium, France, Austria
-
Tasly Pharmaceuticals, Inc.RecruitingChronic Stable Angina PectorisUnited States
-
Roxane LaboratoriesCompletedHypertension | Vasospastic Angina | Chronic Stable AnginaUnited States
-
Benha UniversityCompletedChronic Stable Angina
-
The People's Hospital of Liaoning ProvinceUnknownStable Angina Pectoris | Unstable Angina PectorisChina
Clinical Trials on Xinnaoning Capsule
-
Quan JiangUnknown
-
Guizhou Bailing Group Pharmaceutical Co LtdWangjing Hospital, China Academy of Chinese Medical Sciences; The First Affiliated... and other collaboratorsUnknownKnee OsteoarthritisChina
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
-
Yung Shin Pharm. Ind. Co., Ltd.Changhua Christian HospitalCompletedHot Flashes | PMSTaiwan
-
Chipscreen Biosciences, Ltd.Not yet recruiting
-
Burapha UniversityCompletedAsparagus Capsule ConsumptionThailand
-
Vibrant Ltd.CompletedConstipationUnited States
-
Vibrant Ltd.UnknownConstipationUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownChronic Obstructive Pulmonary Disease
-
Valerie TaylorUniversity of Calgary; Nimble Science Ltd.RecruitingObsessive-Compulsive DisorderCanada